SAN DIEGO, March 13, 2018 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced Nick Boyle,
Ph.D., vice president, business development and marketing, will
present a corporate overview at the B. Riley FBR China Healthcare
Investment & Partnering Symposium 2018 (CHIPS) on Friday, March 16, at 3:30
p.m. China Standard Time, 3:30 a.m.
Eastern Standard Time, in Hangzhou, China.
The live audio webcast from the conference and subsequent replay
may be accessed by visiting Tocagen's website. The
webcast will be available shortly after conclusion of the
presentation and archived on the company's website for 90 days
following the presentation.
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy
company developing first-in-class, broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. Tocagen's lead investigational product candidate,
Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3
trial for recurrent high-grade glioma (HGG), a disease with
significant unmet medical need. The U.S. Food and Drug
Administration (FDA) has granted Toca 511 & Toca FC
Breakthrough Therapy Designation for the treatment of recurrent HGG
and the European Medicines Agency (EMA) has granted Toca 511 PRIME
(PRIority MEdicines) designation for the treatment of HGG. For more
information about Tocagen, visit www.tocagen.com.
Media Contact:
Monica
May
Canale Communications
(619) 849-5383
monica@canalecomm.com
Investor Contact:
Elizabeth
Broder
The Trout Group
(646) 378-2945
ebroder@troutgroup.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/tocagen-to-present-at-the-b-riley-fbr-china-healthcare-investment--partnering-symposium-2018-300612703.html
SOURCE Tocagen Inc.